Gefitinib Tablet trade name Iressa, marketed by AstraZeneca and Tevais is advised for treating certain breast, lung and other cancers. This medication acts by interrupting signalling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR.

Side Effects:

As Gefitinib Tablet is a selective chemotherapeutic agent, its tolerability profile is better than previous cytotoxic agents